Add Company
Join Now

Eyenovia Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Eyenovia's estimated annual revenue is currently $10.5M per year.(i)
  • Eyenovia's estimated revenue per employee is $155,000

Employee Data

  • Eyenovia has 68 Employees.(i)
  • Eyenovia grew their employee count by 3% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.1M7250%N/AN/A
#2
$5.9M3815%N/AN/A
#3
$34.7M2246%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.9M6-14%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$4.2M27-16%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

Eyenovia, Inc. (NASDAQ: EYEN) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. Eyenoviaￃﾢ￢ﾂﾬ￢ﾄﾢs pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, glaucoma, mydriasis and other eye diseases.

keywords:N/A

N/A

Total Funding

68

Number of Employees

$10.5M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Eyenovia News

2022-04-17 - Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to ...

Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator American Society of Cataract and Refractive Surgery (ASCRS)...

2022-04-17 - Eyenovia Announces Poster Presentation at the 2022 ...

NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a...

2022-03-22 - Eyenovia Reports Fourth Quarter and Full Year 2021 ...

Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP)...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.3M68-32%$33.1M
#2
$13.5M68-28%N/A
#3
$7.3M6828%N/A
#4
$12.5M68-9%N/A
#5
$16.5M688%N/A